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Synthesis, analysis and biological evaluation of
novel indolquinonecryptolepine analogues as
potential anti-tumour agents†
A. Le Gresley,* V. Gudivaka, S. Carrington, A. Sinclair and J. E. Brown
A small library of cryptolepine analogues were synthesised incorporating halogens and/or nitrogen con-
taining side chains to optimise their interaction with the sugar–phosphate backbone of DNA to give
improved binding, interfering with topoisomerase II hence enhancing cytotoxicity. Cell viability, DNA
binding and Topoisomerase II inhibition is discussed for these compounds. Fluorescence microscopy was
used to investigate the uptake of the synthesised cryptolepines into the nucleus. We report the synthesis
and anti-cancer biological evaluation of nine novel cryptolepine analogues, which have greater cyto-
toxicity than the parent compound and are important lead compounds in the development of novel
potent and selective indoloquinone anti-neoplastic agents.
Introduction
Cryptolepine (1) has been known for some years to possess
activity as an anticancer agent not only by intercalating into
DNA but also by inhibiting the topoisomerase II. This has led to
a number of derivatives being synthesised incorporating halo-
gens at various ring positions.1–6 Comparison of anti-cancer
activity of cryptolepines with chloro, bromo and iodo atoms at
the 11 position showed considerable variation, with 11-bromo
showing an improved cytotoxicity profile and the 11-chlorinated
compound showing a reduction in the activity compared to the
parent compound in the tested cell lines. Of those synthesized,
7,11-dichlorocryptolepine (2) showed the highest cytotoxic
activity against MAC15a (colon adenocarcinoma) cells with an
IC50 value of 14.4 ± 2.8 μM (after 1 hour exposure).7,8
Whilst the literature is generally in agreement that crypto-
lepines are an interesting target for anti-cancer research, the
mode of action is still not that well understood.9 For example, it
is observed that the cytotoxicity of cryptolepine is linked to its
ability to inhibit the topoisomerase II enzyme so it would be
expected that bromo and iodo compounds would show greater
topoisomerase II inhibition owing to their increased lipophilicity.
Topoisomerase II assay results of these 11-halogenated com-
pounds showed they are responsible for greater inhibition com-
pared to the parent molecule 1, but surprisingly the 11-chloro
derivative showed the highest topoisomerase II inhibition despite
its lower in vitrocyototoxicity.10–12 It was hyptothesised that this
could be due to the changes in drug–DNA interactions or drug
uptake based on the structure and size of the molecule.13
Within this manuscript, we report the synthesis of novel
cryptolepineaminoalkyl- and amidoalkyl-derivatives along with
halogenated cryptolepines, including 11-iodocryptolepine.
These compounds were screened for anti-cancer activity
in vitro against cell lines MCF-7, A549 and DLD-1 using doxo-
rubicin as positive control, data was also obtained pertaining
to rates of cellular uptake and cellular localisation studies. The
previously unreported biophysical and in vitro testing of halo-
genated cryptolepines and novel derivatives are discussed in
an eﬀort to clarify structure activity relationship and address
the inconsistencies vis mode of action within the literature.
Materials and methods
Synthetic chemistry
The synthetic techniques used in the synthesis of the chosen
targets are reasonably well known and details of key coupling
†Electronic supplementary information (ESI) available: Synthetic details and
spectroscopic data. See DOI: 10.1039/c5ob02408k
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and quaternisation reactions are given in more detail under
general procedures. Full spectroscopic data and detailed
methodology is provided in the ESI.† Scheme 1 indicates the
varied routes taken to achieve the synthesis of a series of
amido, amino and halo-derivatised cryptolepines.
Instrumentation
NMR spectra were recorded on Bruker Avance III 400 two-
channel FT-NMR spectrometer (AV400). It is equipped with a
5 mm BBFO+ probe (broadband multinuclear, auto-tune, with
Z-gradients). Spectra were recorded using TopSpin 3.0 pl4, ©
2010 Brüker BioSpin, control and processing software and
Icon NMR 4.5.1 Build 51 for TopSpin 3.0 automation software.
Mass spectra of compounds were obtained using a Waters
LCT-TOF-MS instrument using ESI selective mass detector and
Agilent 5973 GC-MS. High resolution mass spectra of com-
pounds were obtained from Medac labs, UK (BS EN
ISO9001:2008) using Waters LCT Premier (ES-ToF)/Acquity
i-Class mass spectrometer. Infrared spectra were recorded on
Thermo Scientific™ Nicolet™ iS™5 FT-IR Spectrometer.
Melting points were measured using Gallenkamp digital
melting-point apparatus 5A 6797. Up to 350 °C (division:
0.1 °C. 220 V) unless otherwise stated, all the chemicals used
in the synthesis were purchased from Sigma Aldrich, UK.
General procedures
Specific details of intermediate synthesis and spectroscopic
data are found in ESI.† The below general procedures outline
the final synthetic steps for the cryptolepine derivatives as
indicated in Table 1.
General procedure for quaternisation A (4d, 5a–5c). Under
dry conditions, 10H-indolo[3,2-b]quinoline (or its 11-halo
derivative) and methyl/ethyl triflate were stirred in anhydrous
toluene for 24 hours at room temperature. The reaction
mixture was poured in diethyl ether and the resulting yellow
precipitate was collected by filtration. Aqueous ammonia solu-
tion (3.3% v/v) was added to the precipitate and the mixture
was stirred to convert the product to its free base form. Then
the mixture was extracted using chloroform (4 × 75 ml). The
collected organic layers were combined and evaporated
in vacuo to give the crude product which was then purified by
column chromatography on silica gel by using DCM :
methanol : NH4OH (5 : 1 : 0.1) as the eluent. Finally the free
base was converted to its hydrochloride salt by neutralising
with 0.1 M methanolic hydrochloric acid (5 ml) and then solu-
tion was evaporated in vacuo to give the desired N5-methyl or
N5-ethyl cryptolepine derivative, as a yellow coloured solid.
General procedure for quaternisation B (1 & 4a–4c). Methyl
iodide was added drop wise to a solution of sulfolane and
11-bromo-10H-indolo[3,2-b]quinoline and stirred under nitro-
gen for 16 hours at 50 °C. The reaction mixture was cooled to
room temperature then ether (25 ml) and methanol (5 ml)
were added to induce precipitation. Diethyl ether (25 ml) was
added and then the mixture was filtered and the solid was
dried in vacuo. The solid was mixed with aqueous sodium car-
bonate solution (10% w/v, 30 ml) followed by extraction with
chloroform (4 × 30 ml). The organic layers were combined and
dried using magnesium sulfate and filtered. The solvent was
removed in vacuo to concentrate the solution which was then
treated with a solution of methanolic hydrochloric acid (0.1%
v/v) drop wise to give hydrochloride salt of cryptolepine as a
bright yellow coloured solid.
General procedure for amide coupling reaction C (5a–5c).
To finely ground 10H-indolo[3,2-b]quinoline-11-carboxylic
acid, dichloromethane and DMF were added and the mixture
was stirred for 15 min. NEt3 was added drop wise under con-
tinuous stirring before adding COMU to the solution, which
was then stirred for 10 min. The desired amine was added
drop wise and the reaction mixture was stirred for 16 hours at
room temperature.
The reaction mixture was added to ethyl acetate (100 ml)
and extracted with aqueous 1 M HCl solution (2 × 30 ml) and
aqueous 1 M sodium bicarbonate solution (2 × 30 ml). Then
the organic layers were collected and dried using magnesium
sulphate and evaporated in vacuo to give the crude quindoline
amide, which was purified by column chromatography over
silica gel using ethyl acetate : hexane (1 : 1) and dried in vacuo
to give desired alkylamidoquindoline.
General procedure for 11-chloro substitution D (3a–3e). To
a solution of 11-chloro-5-methyl(or ethyl)-10H-indolo[3,2-b]qui-
nolin-5-ium chloride (4c) in ethyl acetate, the desired amine
was added and the contents of the flask were heated to reflux
for 16 hours. The reaction mixture was cooled down to room
temperature and the precipitate was collected by filtration and
washed with diethyl ether and dried in vacuo to give yellow
coloured crystals.
Biological methods
General. RPMI culture medium, DMEM culture medium,
Foetal bovine se-rum (FBS), penicillin–streptomycin solution
(10 000 U per mL penicillin, 10 mg per mL streptomycin),
L-glutamine (200 mM), Trypsin, Trypan blue solution, MTT,
Doxorubicin, Dimethyl sulfoxide (DMSO) (biological grade)
were obtained from Sigma Aldrich, UK. 96 well culture plates,
T75 ml flasks, and pipettes were purchased from Fischer
Scientific, UK. Plate reader used to scan the 96 well plates was
Lab-tech LT-4000. The Incubator used to grow the cells was
from Thermo Scientific, UK. The human cell lines, MCF-7,
A549 and DLD-1 cells were kindly provided by the Institute of
Cancer Therapeutics, Bradford University, Bradford, UK.
Cell line culturing. The three cell lines were cultured in
RPMI medium supplemented with 10% heat inactivated foetal
bovine serum, 10 000 U per mL penicillin, 10 mg per mL strep-
tomycin and 200 mM L-glutamine. Cells were grown in 95%
humidified air mixed with 5% carbon dioxide at a fixed temp-
erature of 37 °C. Exhausted growth medium was replaced with
fresh growth medium every two days. When the cells reached
90% confluence, they were sub-cultured. Firstly, in a laminar
flow chamber, the media was removed and the cell were
washed with 15 ml of PBS and then 2.5 ml of trypsin-EDTA
solution was added then incubated for 5–7 min to allow the
cell splitting to takes place. Then cells were observed under a
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Scheme 1 Synthetic route for the cryptolepine derivatives. (a) POBr3 PBr3, 16 h, reﬂux (b) POCl3, PCl5, 4 h reﬂux. General procedures are given as
Proc. A–D and are discussed in more depth in the methods section: (A) methyl/ethyl triﬂate, 34 h, RT (B) MeI, sulfolane 16 h RT (C) COMU, Et3N,
DCM 16 h RT (D) EtOAC, amine, 16 h, reﬂux.
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light microscope (20×) to check if they were detached. If
needed they were tapped gently to detach from each other.
Fresh growth medium (10 ml) was added and the suspension
was aspirated using a pasture pipette. For further culturing
2 ml of that suspension was taken and added to 20 ml of fresh
growth medium in a T75 flask and incubated.
Growth curves. Growth curves were plotted on three cell
lines MCF7, A549 and DLD-1 to observe the growth character-
istics of the cells. The MTT assay was used to determine the
growth of the cells over the course of time. Cells were seeded
in a series at varying densities (500, 1000, 2000, 4000, 8000,
16 000, 32 000 and 64 000) at a final volume of 200 µL and
incubated for 96 hours. Two-hundred microliters of the growth
medium without cells served as the blank for the assay. Follow-
ing incubation, the medium was removed and 25 µL of the
MTT reagent (concentration) was added to each well and incu-
bated for 3 hours. The purple formazan crystals were solubil-
ised with 100 μL of DMSO and gentle shaking. Plates were
then left in the dark for an hour and were then scanned at
570 nm using a plate reader. A graph was plotted with the
average absorbance on the Y-axis and cell count on the X-axis.
This was replicated thrice on the same plate in three rows.
MTT/ATP assay. DMSO (biological grade) was used to dis-
solve cryptolepine and its analogues to reach a drug concen-
tration of 10 mM (stock solution A). Serial dilutions of stock
solution A were prepared (100 µM, 10 µM, 1 µM, 0.1 µM,
0.01 µM and 0.001 µM) at a final volume of 10 mL. All of the
drug solutions made were stored at −20 °C and thawed when
required for the MTT assay experiment. The final concen-
tration of DMSO in the working stocks did not exceed 0.1%
v/v. Twenty thousand cells were seeded per well and treatment
applied after 24 hours. After X hours of treatment, the
medium was removed (including control cell-free wells) and
the MTT assay carried out as described in the previous section.
After MTT treatment purple coloured crystals were observed
under the microscope then medium from each well was care-
fully removed and 100 μL of DMSO were added to dissolve the
precipitate and the plate was left in the dark for an hour. The
obtained raw data was then analysed using MS-Excel (2010)
software and the IC50 values were calculated using the Graph-
Pad Prism software (version 6.0).
Topoisomerase II inhibition studies. A topoisomerase II
assay kit was purchased from Topogen, Florida, USA (Topogen,
2005) – kDNA, decatenated kDNA marker, Linear kDNA
marker, gel loading buﬀer, protein kinase buﬀer A: mixture of
Tris-HCl (pH-8) (0.5 M), NaCl (1.50 M), MgCl2 (100 mM),
dithiothreitol (5 mM), bovine serum albumin (BSA)
(300 µg mL−1). Buﬀer B: 20 mM ATP in water : drugs :
cryptolepine and its analogues Eppendorf tubes, Micro pip-
ettes and pipette tips, A grade glassware. 1% Agarose gels were
prepared (0.75 g agarose in 75 mL tris buﬀer) and ethidium
bromide (0.5 µg mL−1) added to the solution. The solution was
allowed to solidify at room temperature for an hour prior to
loading. Running Buﬀer (TAE buﬀer): 50× concentration: tris
base (242 g), glacial acetic acid (57.1 mL) and of 0.5 M EDTA
(100 mL). Diluted to 1× cryptolepine and its analogues were
initially dissolved in DMSO and then diluted to reach the
desired concentration. Serial dilutions were carried out to
produce a concentration range of 100 µM to 0.01 μM. The
maximum DMSO concentration did not exceed 0.1% v/v.
Buﬀer (2 μL complete reaction buﬀer = buﬀer A + buﬀer B in
1 : 1 ratio), kDNA (0.25 μg mL−1, 1 μL), bovine serum albumin
(30 μg mL−1, 1 μL), distilled water (to make up to 20 μL), drug
to be tested in desired concentration (1 μL) were pipetted out
to a Eppendorf tube and incubated for 30 minutes at 37 °C.
The reaction was then stopped by adding 4 μL of stopping
buﬀer and 2 μL of protein kinase. The mixture was then incu-
bated for digestion for 30 minutes. The reaction products were
then loaded on to the ethidium bromide-agarose gel and electro-
phoresis was carried out at 65 V for 2.5 hours in TAE buﬀer. After
the separation, the gel was visualised under UV illumination.
Fluorescence microscopy. Using BD-Falcon 8 chambered
culture slides, A549 cells were grown in RPMI medium without
any indicator. A cell seeding density of 4000 cells per well was
determined as optimum and was used for fluorescence
microscopy. After 17 hours of incubation, the chamber slides
were taken out and the medium was carefully removed and
loaded with the desired concentration of the drug solution in
RPMI medium and further incubated for 1 hour. Cells were
gently washed with PBS (37 °C), stained with DAPI nuclear
stain (5 mg ml−1) and shielded using a fluoro-shield solution
to protect from photo bleaching. A cover slip was placed on
the slide ensuring no air bubbles formed and sealed. Drug
localisation in the cells was observed under the microscope at
40× magnification. Firstly, images were captured under normal
light at 40× magnification and then using fluorescent filters,
the blue cell nuclei were captured. By changing the filter to
green again the whole cells were observed to see the drug local-
isation. Finally both the nuclei and whole cell images were
overlayed using the Leica microscopy imaging software.
In vitro drug-uptake studies. Cryptolepine and its deriva-
tives were dissolved in methanol and the solutions were
Table 1 Yields for synthesised halo-, alkylamino- and alkylamido
analogues
Compound Yield (%)
1 N/A
3a 61b
3b 68b
3c 67b
3d 23b
3e 35a,b
4a 11
4b 65
4c 56
4d 74a
5a 83b
5b 91b
5c 12b
aDenotes the ethyl quaternary ammonium salt rather than methyl,
which is the case for the rest. Details of the synthetic methodology and
supporting spectroscopic data are available in ESI. bDenotes the
synthesis compounds first reported in this paper.
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scanned using a UV spectrophotometer and the λ-max was
recorded. Using these wavelength readings, samples were
excited using a fluorescent spectrophotometer to record their
emission wavelengths.
Cells were grown in a 96 well plate for 24 hours in phenol
red-free RPMI medium at a seeding density of 20 000 cells per
well. Seven rows of 3 columns (7 × 3 = 21 wells) were loaded
with cell suspension for incubation. Twenty four hours post
incubation, media from the first row of the cells was removed
and loaded with 100 μL of drug solution (solvent = media)
with a concentration of 10 μM and the plate was placed back
in to the incubator. After 30 min. the plate was removed from
the incubator and the media from the second row was
removed and loaded with 100 μL of drug solution (10 μM). The
same procedure was repeated for the remainder of the rows
every 30 minutes, leaving the last row with no treatment
(blank). After the treatments were complete, the drug solutions
were gently removed and 100 μL of DMSO was added to the
wells and shaken gently for 30 minutes. The positive control
wells were filled with 100 μL of 10 μM drug solution.
Cells were lysed using Triton X-100 (a non-ionic surfactant
which increases the cell permeation) and the drug was
extracted using methanol. The plate was then scanned using a
fluorescence plate reader measuring the intensity of the fluo-
rescence from each well (25 scans for each well). The 8th was
filled with 10 μM drug solution, which served as a positive
control for the experiment. Using a positive control (100%
drug solution), data was analysed and compared to generate
the report of percentage drug uploaded into the cells over the
period of three hours.
Drug–DNA binding assay. Duplex DNA (DS26) and quadru-
plex DNA (AG23) oligonucleotides were purchased from Euro-
genetic, Belgium. Fluorometric titrations were performed on
Varian-Cary Eclipse fluorescence spectrometer (scans at
24 000 nm min−1, radiation source is Xenon flash lamp with
room light immunity) with carry eclipse spectrophotometric
software. Sodium cacodylate was purchased from Sigma
Aldrich, UK. Made using 0.2 M sodium cacodylate and 0.2 M
HCl thiazole orange was purchased from Sigma Aldrich, UK.
Cacodylate buﬀer was made by dissolving sodium cacodylate
crystals (42.8 g) in distilled water (1 L) and the pH was adjusted
to 7.3 using aqueous HCl solution (0.2 M). The G-quadruplexes
were made by heating the 22AG nucleotide in the cacodylate
buﬀer (10 mM, pH 7.3), 100 mM KCl at 90 °C for five minutes
and then the solution was cooled in ice to form G-quadruplexes
by intermolecular folding. This duplex nucleotide sequence was
made by heating DS26 in the cacodylate buﬀer (10 mM, pH 7.3),
100 mM KCl at 90 °C for five minutes and then slowly cooling
over a period of 6 hours. Once these DNA solutions were made,
the concentrations were measured using the UV-VIS spectro-
photometer at 260 nm using their extinction coeﬃcient values.
Cacodylate buﬀer containing 100 mM of KCl was used for all
the dilutions to get desired concentrations. In a 3 mL capacity
cuvette, 1 mL of thiaozole orange solution and 1 mL of DS26
solution were pipetted and then the volume was adjusted to
3 mL using the blank buﬀer. The fluorescence was measured
using the fluorimeter. This served as a control for the titration.
For the ligand binding experiments, first 1 mL of thiozole
orange and 1 mL of DS26 solution were put into a cuvette and
then the total concentration of ligand was made to 0.375 μM by
adding the desired ligand and the volume was made up using
the cacodylate buﬀer. The solution was allowed to equilibrate
for 3 min and then the fluorescence intensity was measured.
The same was repeated for each fluorometric titration by
increasing the concentration of ligand to 0.75 μM, 1.5 μM,
3.0 μM, 4.5 μM, 7.5 μM in the cell and keeping the total
volume of the cell constant at 3 mL. The same procedure was
carried out for the G-quadruplex sequence with the only diﬀer-
ence being the concentration of thiazole orange used which
was compared to DS26. The reason for this is that quadruplex
sequence has a smaller number of binding sites compared to
the duplex sequence of DS26. During the titration, depending
on the activity of the ligand, a gradual fall in the fluorescence
was seen as the concentration of the ligand increased.
All the concentrations were recorded using the Carry Eclipse
software and the integral graphs were plotted for each ligand
concentration measured. The decrease in percentage of fluo-
rescence intensity was measured for each ligand concentration
and hence the binding eﬃciency of the ligand was interpreted.
Results – synthesis
In addition to probing the halocryptolepine activity, alkyl-
amino side chains were attached to increase lipophilicity and
improve overall drug uptake. For the same reason alkylamino
side chains with diﬀerent lengths were selected to see if there
is any correlation between side chain length and the drug
uptake in the cell lines in vitro.
11-Chlorocryptolepine served as the key intermediate to
make the derivatives with amino linkages at 11-position via
nucleophilic substitution (see general procedure D). In the
derivatives with amino linkages, it is unlikely that the second-
ary amine present on the side chain can be protonated at
physiological pH but it is possible that the positive charge
arising from the pyridinium nitrogen (Fig. 1) can resonate to
transfer the positive charge to the side chain. This structure
can potentially better interact with the negatively charged
phosphate backbone of DNA which should ultimately lead to
improved binding interactions.
Unlike derivatives with amino linkages, in the derivatives
with amido linkages, the positive charge will not be able to
move to the aromatic ring (Fig. 1). So these compounds were
made to see how having an amide bond between side chains
and the aromatic system of cryptolepine will aﬀect the cytotoxi-
city and the in vitro drug uptake in cancer cells.
Results – in vitro and biophysical testing
Three diﬀerent cancer cell lines: MCF-7 (breast cancer) A549
(lung cancer) DLD-1 (colon cancer) were used to test the anti-
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cancer activity of the synthesised cryptolepine analogues. In
addition to ease of culture and laboratory maintenance, choos-
ing these cell lines make it possible to compare the results
with previous literature.14a–c All three cell lines incubated with
cryptolepine 1 for 96 hours, showed anti-proliferative activity.
The greatest activity was against A459 cells with an IC50 value
of 0.47 ± 0.12 μM compared to MCF-7 and DLD-1 cells on
which it gave IC50 values of 5.9 ± 0.69 μM and 1.25 ± 0.77 μM
respectively (Table 2), which are in agreement with similar
experiments carried out by Gokcek et al. on A-549 and DLD-1
cells and reported IC50 values of 0.55 ± 0.05 μM and 1.44 ±
0.002 μM.15 From the dose response curve it is observed that
no significant activity was seen until a 0.10 μM concentration
of cryptolepine was applied. After that there was a gradual
downward trend until 1.00 μM. Once the concentration
reached 10 μM, the percentage cell survival was essentially
zero.
Cell viability
After exposing cells to 1 μM or higher It was observed under
the microscope that cells started changing morphology. As the
concentration increased, more cells were lysed and more cell
debris was observed. Compounds 3b and 3c showed a higher
level of activity compared to 3a suggesting that having an alkyl-
amino side chain is structurally significant. In particular, com-
pound 3b showed 10 times greater activity than the parent
compound 1 with an IC50 value of 0.63 ± 0.51 μM. Interestingly
3c derivative showed a greater activity than 3b for A549 and
DLD-1 cells with IC50 values of 0.83 ± 0.28 μM and 2.4 ± 0.96
respectively (Fig. 2).
Unsurprisingly, these results indicate the dependence of
the activity in the specific cell line being tested, however the
results of testing against cancer cell lines suggest that alkyl-
amino amino side chains may be useful in forming electro-
Fig. 1 Possible resonance structure for 11-aminocryptolepine derivatives.
Table 2 In vitro and biophysical test results for the synthesised derivatives 3a–3e, 4a–4d and 5a–5c for comparison with cryptolepine 1. MIC for
topoisomerase II inhibition refers to the minimum inhibititory concentration as per Bonjean et al.10
Compound
A549 cells
IC50 (μM)
MCF-7 cells
IC50 (μM)
DLD-1 cells
IC50 (μM)
Topoisomerase II
inhibition MIC (μM)
DS26 binding
(Kd)
22AG binding
(Kd)
1 0.47 ± 0.12 5.90 ± 0.69 1.25 ± 0.77 0.5 1.62 ± 0.62 2.45 ± 0.36
3a 20.38 ± 2.01 17.92 ± 2.31 37.05 ± 2.36 — 2.51 ± 0.33 39.81 ± 5.17
3b 1.05 ± 0.15 0.63 ± 0.51 2.85 ± 0.87 0.25 0.79 ± 0.37 5.01 ± 1.85
3c 0.83 ± 0.28 4.253 ± 1.88 2.4 ± 0.96 — 1.26 ± 0.26 6.31 ± 3.15
3d 10.41 ± 0.75 6.77 ± 2.03 12.23 ± 1.20 — 2.51 ± 0.58 3.98 ± 1.53
3e 12.58 ± 2.12 43.59 ± 4.72 26.73 ± 3.92 1.55 ± 0.55 26.92 ± 6.96
4a 5.16 ± 1.25 2.15 ± 0.41 3.35 ± 1.62 — — —
4b 0.28 ± 0.1 0.1 ± 0.02 0.34 ± 0.05 0.10 ± 0.06 0.32 ± 0.10
4c 42.83 ± 3.74 62.87 ± 2.71 81.58 ± 2.61 0.25 0.40 ± 0.20 0.63 ± 0.02
4d 15.24 ± 2.20 21.00 ± 3.62 31.84 ± 3.86 — — —
5a 42.64 ± 3.17 31.72 ± 2.56 75.01 ± 2.92 >100 — —
5b 21.41 ± 1.76 7.26 ± 1.24 4.14 ± 0.89 — 2.00 ± 0.74 3.55 ± 1.04
5c 12.38 ± 2.16 9.15 ± 1.56 15.21 ± 3.23 — — —
Paper Organic & Biomolecular Chemistry
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static interactions with the negatively charged DNA back-
bone.16,17 Addition of a hydrophilic motif as in the case of 3d
failed to improve upon the anticancer activity, however it was
shown to still be superior to the more lipophilic 3b derivative.
The derivative 3d is actually similar to mitoxantrone and
showed greatest activity on the breast cancer cells with an IC50
value of 6.77 ± 2.03 μM. This selectivity was also observed when
Von Hoﬀ and his team tested mitoxantrone on 20 diﬀerent
tumour cell lines, where greatest activity against breast cancer
(MCF-7) cells compared to DLD-1 cells was observed.18a,19 The
anti-proliferative activity shown by 4b was most potent, with 4a
showing the second highest activity among all the halogenated
compounds tested. The 11 halogenated analogues followed a
downward trend of activity from 11-iodo to the 11-chloro deriva-
tive indicating the importance of a lipophilic group in the 11
position. The importance of halogen interactions has been
reported by Sarwar et al. where the potential for encapsulation
augments the role of halogen interactions, which are negligible
in comparison with the bulk solvent interactions.18b
This van der Waals interaction between iodine and amino
hydrogens is important (3.43 ± 0.33 A) for optimal binding
and selectivity of drug towards that particular DNA sequen-
ce.18a A gradual decrease in the DNA-binding has been
similarly observed from iodo to fluoro analogues of Calichea-
micine. This could mean that the presence of Iodine atom at
11-position may have been involved in similar molecular inter-
actions which were contributing for the DNA binding
eﬃciency of 4b.
Derivatives 5a–5c showed comparatively less activity than
the other sets. Amongst the amido-derivatives, 5c showed the
highest activity whereas the 5a derivative showed lowest
activity. Regardless of whether it is an amino derivative and an
amido derivative, the isopropyl group reduced the activity sig-
nificantly, possibly due to the steric hindrance imparted by the
isopropyl functional group.
Amongst all the molecules synthesised, derivatives with
11-alkylamino linkages and 11-halogenated compounds
showed comparatively greater activity than compounds having
11-amido side chains.
Topoisomerase II inhibition studies
Cryptolepine has been tested for topoisomerase II activity in
the past using both of the methods outlines above and it has
been proposed that cryptolepine acts as a topoisomerase II
poison.20,21 A random derivative was selected from each set for
Topoisomerase II testing. When cryptolepine 1 was tested for
its topoisomerase II activity it gave a minimum inhibitory con-
centration value (MIC) of 0.5 μM. The same result was reported
by Bonjean and his team on supercoiled plasmid DNA
obtained from Escherichia coli.10
Cryptolepine 3b showed the highest topoisomerase II inhi-
bition of the compounds tested and also the highest overall
cytotoxicity. This continues to support the link between the
two. The analogue 5a gave much lower topoisomerase II
activity than the parent compound; however the 4c derivative
failed to confirm this correlation between Topoisomerase II
inhibition and cytotoxicity. The topoisomerase II activities
obtained from both compounds 3b and 4c are significantly
higher than that of the parent compound.
It is possible that the lack of correlation between Topo-
isomerase II inhibition and cytotoxicity may be due to diﬀer-
ences in the pharmacokinetics profile of the compounds in so
drug uptake was investigated.
Fluorescence microscopy
Fluorescence microscopy was used to investigate whether the
derivatives were reaching the nucleus by crossing the cellular
membrane and nuclear envelope. For this experiment A549
cells were selected by observing the morphology under a
microscope. Though the cultured cells are in monolayers,
MCF-7 and DLD-1 cells tend to form clusters in the culture
plate whereas A549 cells are evenly spread. Out of the com-
pounds scanned, 4a–4c and 3b emitted high enough fluo-
rescence intensity to facilitate fluorescence microscopy.
Derivative 3b was selected as one of the most active and 4c was
included with view to identifying the reason for its low cytotoxi-
city despite high topoisomerase II activity. Fluorescence micro-
scopic pictures were taken for both DAPI and the cryptolepine
derivatives by exciting them at their respective excitation wave-
lengths and then overlaying them to identify co-localisation.22,23
Co-localisation of DAPI and 3b in the nucleus of A549 cells
indicated that although 3b was spread all over the cell, high
concentrations are localised at nucleus, which was clearly seen
in the pictures as more bright fluorescence was arising from
the nucleus of the cell which is co-localised with DAPI (Fig. 3).
The same was observed with 4c but the fluorescence inten-
sity seemed to be lower than 3b (Fig. 4). This is supported by
similar experiments conducted by Redshaw et al. to see the cel-
lular localisation of fluorescent zinc complexes using DAPI as
a counterstain.24
These drug localisation experiments only gave information
about whether the drug is present in the nucleus or not. By
measuring the amount of drug taken up by the cells after treat-
ment for particular time will give quantitative information
about the rate of drug uptake in the cells.
Fig. 2 Dose–response curve for 1 against MCF 7 (-○-), A549 (□) and
DLD-1 (△) cancer cell lines.
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In vitro drug uptake studies
To carry out the drug uptake studies A549 cells were selected
because, after drug treatment, they make evenly spread mono-
layers. MCF-7 and DLD-1 cells tend to form clusters in the
culture plates this was observed under microscope while per-
forming cytotoxicity assays. Based on the observed lack of cell
expansion the images suggest apoptosis as the pathway and
this is supported by the literature.25
Drug uptake was determined using the method of Kunwar
et al.26 Fluorescence intensity was measured and compared
using a positive control of the same drug solution and result
was expressed as percentage drug uptake. Cryptolepine deriva-
tives from each set were chosen at random. The amount of
fluorescence exhibited by each drug can be diﬀerent, so the
same drug was taken as positive control (without any cells
being present – 100%) percentage drug uptake was calculated.
This percentage drug uptake was directly proportional to the
amount of drug present in the cells.
Looking at the in vitro drug uptake results, 3b was taken up
into the cells more quickly than any other compounds tested
reaching 40% within first 30 min after drug treatment, then it
continued to rise up to 60% in 1.5 hours. After 1.5 hours per-
centage drug uptake started to decrease reaching to a 20% at
3 hours this could be due the oozing of cellular contents along
with drug from ruptured cell membranes of dying cells. This
high rapid percentage drug uptake in to the cells may be the
reason for high activity of 3b (Fig. 5).
In the case of 4c, the percentage drug uptake only reached
25% in the first 30 minutes and then increased to 40% after
2 hours then it started to decline and reached about 30% after
three hours. This lower uptake rate might be the reason
behind the lower cytotoxicity of 4c. Another important issue in
the drug uptake profile of this compound was that the intra-
cellular concentration of 4c did not fall as quickly as 3b. This
may be due to lower cytotoxicity of the 4c.
11-Isopropylaminocryptolepine 3a gave a poor uptake
profile with a percentage uptake of 8% in the first thirty
minutes which is 6 times lower compared to 3b and approxi-
mately 4 times lower than the parent compound 1. The
maximum drug uptake for 3a of 18% was seen at 2.5 hours
which is 3 times lower than 3b.
Drug–DNA binding
Since cryptolepines have the potential to act as an anticancer
agent by intercalating into DNA, it was felt prudent to investi-
gate binding eﬃciencies to see whether the novel derivatives
showed improved binding with respect to 1. The aim was also
to better understand the mode of action to address the coun-
terintuitive relationship between for example, the high topo-
isomerase II activity, yet low cytotoxicity for 4c.
Fluorescence displacement assay was selected as method of
choice for the current project for its robustness and the fact
that we could use diﬀerent types of DNA sequences (duplex,
quadruplex) to test a group of random cryptolepine derivatives
covering the diﬀerent classes synthesised.
Using this fluorimetric titration assay, cryptolepine deriva-
tives were tested for their selectivity and eﬃciency of DNA
binding. This assay was done using two types of DNA
sequences; one was a duplex-forming DNA (DS26) and the
other was quadruplex-forming DNA (22AG).
22AG is an oligonucleotide which is similar to the human
telomeric sequence. It is a repeat of the [5′-AG3(T2AG3)3-3′]
which forms G quadruplex DNA. DS26 is a self-complementary
DNA sequence 5′-CA2TCG2ATCGA2T2CGATC2GAT2G-3′] which
form a duplex DNA.24 The gradual decrease in the fluorescence
arising from displacement of thiazole orange from quadruplex
and duplex DNA is used to profile the binding upon gradual
increase of the ligand concentration.
Reference to Table 2 shows that the 11-halocryptolepines 4b
& 4c had the best DNA binding overall with slightly more
selectivity towards duplex DNA over G-quadruplex DNA. The
Fig. 3 Showing co-localisation of DAPI and drug in the nucleus of
A549 cells. Magniﬁcation: 40×, green: 3b (A), blue: DAPI nuclear dye (B),
overlay of both 3b and DAPI (C).
Fig. 4 Showing co-localisation DAPI and drug in the nucleus of A549
cells. Magniﬁcation: 40×, green: 11-chloro cryptolepine, blue: DAPI
nuclear dye, overlay of both drug and DAPI.
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11-iodo compound 4b showed the highest DNA binding con-
stant in both duplex and quadruplex sequences. This
reinforces the cytotoxicity data as high cytotoxicity was shown
by the 11-iodo compound 4b. Interestingly the 11-chloro
derivative 4c showed better DNA binding eﬃciency than
parent molecule despite having a poorer cytotoxicity profile.
The 11-alkylamino derivatives 3a–3e showed better DNA
binding than 1, especially the molecules 3b and 3c with the
11-butylamino and pentylamino side chains. The same pattern
of DNA binding for this class of cryptolepine derivatives was
observed for the cytotoxicity data. The 11-isopropylamino
derivative 3a showed binding eﬃciency to G-quadruplex which
is 16 times lower than its duplex DNA aﬃnity. When compared
to 1, 3b and 3c derivatives showed higher binding eﬃciency to
duplex DNA, implying that the compounds with 11-alkylamino
side chains prefer duplex DNA over quadruplex DNA.
Even though derivative 3d with the aminoalcohol side
chain did not show particularly strong binding to duplex DNA,
its quadruplex binding eﬃciency is considerably higher than
derivatives 3a–3c. More importantly there is not much selecti-
vity of 3d for duplex or quadruplex DNA.
Derivative 5b was selected from the 11-alkylamido class as
it showed higher cytotoxicity compared to the other 11-alkyl
amido derivatives. It showed less binding eﬃciency towards
both duplex and quadruplex DNAs when compared to 1 but it
showed better quadruplex binding than the 11-alkylamino
derivatives implying that it prefers G-quadruplex structures
than duplexes. Overall cryptolepines appear to bind preferen-
tially to duplex DNA over G-quadruplex DNA, this may be
because of its selectivity towards GC rich sequences present in
the duplex DNA.27
Conclusions
The purpose of this study was to attach halogens (Cl, Br and I)
and amino/amido-alkyl side chains at the 11-position of
cryptolepine and then investigate these molecules for anti-
Fig. 5 Showing the rate of drug uptake of a range of cryptolepine derivatives in A549 cells.
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cancer activity using established in vitro cytotoxicity assay and
biophysical studies including DNA binding assays, topoisome-
rase II assays, fluorescence microscopy and quantitative drug
uptake studies.
Of the novel derivatives synthesised the 11-aminoalkyl and
11-halo cryptolepines (3a–3d & 4a–4c resp.) showed greater
activity than those with 11-amido side chains (5a–5c). Overall,
the 11-iodo 4b and the 11-butylamino 3b derivative showed
the highest activity (Table 2). The reason for the enhanced
cytotoxicity of 3b could be the lipophilic alkyl side chain
which may facilitate faster drug-uptake by the cells.
Topoisomerase II results reinforced the link between the
cytotoxicity and topoisomerase II inhibition. Surprisingly,
despite its lower cytotoxicity, the 11-chloro derivative 4c
showed the highest topoisomerase II activity with an MIC
value of 0.25 μM. When analysing its drug uptake profile,
the percentage drug uptake was lower than both the
11-butylamino derivative 3b and parent cryptolepine 1,
reaching an intracellular concentration of only 25% in the
first 30 minutes. In contrast to this despite its lower topoi-
somerase II activity, 11-iodocryptolepine 4b (MIC = 0.5 μM)
gave a higher cytotoxicity value compared to the
11-chlorocryptolepine.
Fluorescence microscopic images showed that, although 3b
was dispersed throughout the cell, high concentrations were
localised in the nucleus. Despite this also being observed in
11-chlorocryptolepine 4c, the amount of drug localised in the
nucleus is dramatically lower than for 3b. This indicates not
only that a smaller amount of the 4c is being taken up by the
cells but also that it is not reaching the nucleus eﬀectively. We
have also shown that 5-ethyl cryptolepines (3e & 4d) have sub-
stantially lower anti-cancer activity that 5-methyl derivatives
and make unlikely lead compounds.
We report the synthesis, characterisation and in vitro
testing of two new classes of cryptolepine derivatives and have
considered their interaction with topoisomerase II and as DNA
intercalators. In addition, we highlight that whilst topoisomer-
ase II inhibition is a potentially important mode of action for
cryptolepine anti-cancer activity, the direct intercalation of
duplex DNA as well as cell permeability significantly influence
the anti-cancer profile of any such derivative. This is important
in deciding what potential anticancer motifs derivatives of this
class of molecule will require to enhance activity and selecti-
vity. Our group is currently working on the combination of
halogenations and substitution of the crypolepine with amine
bearing moieties.
In conclusion, this work has shown that novel amino
and halogenated cryptolepine analogues have greater in vitro
cytotoxicity than the parent compound and are important
lead compounds in the development of novel potent and
selective indoloquinone anti-neoplastic agents. Further syn-
thesis of derivatives which incorporate the amino and
halogen groups may yet result in enhanced activity and
potential selectivity for G-quadruplex DNA, leading to in-
direct telomerase inhibition, which are currently being
investigated.
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